Comparative Pharmacology
Head-to-head clinical analysis: EVOMELA versus OXALIPLATIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EVOMELA versus OXALIPLATIN.
EVOMELA vs OXALIPLATIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
EVOMELA (melphalan) is a bifunctional alkylating agent that forms cross-links between DNA strands, inhibiting DNA replication and transcription, leading to cell death.
Oxaliplatin is a platinum-based alkylating agent that forms inter- and intrastrand DNA crosslinks, inhibiting DNA replication and transcription, leading to cell death.
140-200 mg/m² IV over 30 minutes for conditioning prior to ASCT; off-label: 16 mg/m² IV over 15-20 minutes every 4 weeks for MM.
85 mg/m² intravenously over 2 hours every 2 weeks in combination with 5-fluorouracil and leucovorin (FOLFOX regimen).
None Documented
None Documented
Terminal elimination half-life is approximately 75 minutes (range 40-120 minutes) in patients with normal renal function; prolonged to 180-300 minutes in renal impairment
Clinical Note
moderateOxaliplatin + Digoxin
"Oxaliplatin may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateOxaliplatin + Digitoxin
"Oxaliplatin may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateOxaliplatin + Deslanoside
"Oxaliplatin may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateOxaliplatin + Acetyldigitoxin
"Oxaliplatin may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal elimination half-life is approximately 40-50 hours for ultrafilterable platinum (active species) and 240-500 hours for total platinum (bound to plasma proteins and erythrocytes). The prolonged half-life reflects slow release from tissue binding.
Primarily renal: approximately 10-30% of unchanged drug excreted in urine within 24 hours; extensive hepatic metabolism; fecal excretion accounts for <5%
Renal excretion accounts for approximately 50% of the administered platinum, with the remainder eliminated via biliary/fecal routes. Platinum accumulates in erythrocytes and is slowly cleared.
Category C
Category D/X
Alkylating Agent
Alkylating Agent